These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38876155)

  • 21. Nirsevimab: First Approval.
    Keam SJ
    Drugs; 2023 Feb; 83(2):181-187. PubMed ID: 36577878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Balanced on the Biggest Wave: Nirsevimab for Newborns.
    McPherson C; Lockowitz CR; Newland JG
    Neonatal Netw; 2024 Apr; 43(2):105-115. PubMed ID: 38599778
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Coadministered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine.
    Peterson JT; Zareba AM; Fitz-Patrick D; Essink BJ; Scott DA; Swanson KA; Chelani D; Radley D; Cooper D; Jansen KU; Dormitzer PR; Gruber WC; Gurtman A
    J Infect Dis; 2022 Jun; 225(12):2077-2086. PubMed ID: 34637519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonadjuvanted Bivalent Respiratory Syncytial Virus Vaccination and Perinatal Outcomes.
    Son M; Riley LE; Staniczenko AP; Cron J; Yen S; Thomas C; Sholle E; Osborne LM; Lipkind HS
    JAMA Netw Open; 2024 Jul; 7(7):e2419268. PubMed ID: 38976271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants.
    Drysdale SB; Cathie K; Flamein F; Knuf M; Collins AM; Hill HC; Kaiser F; Cohen R; Pinquier D; Felter CT; Vassilouthis NC; Jin J; Bangert M; Mari K; Nteene R; Wague S; Roberts M; Tissières P; Royal S; Faust SN;
    N Engl J Med; 2023 Dec; 389(26):2425-2435. PubMed ID: 38157500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Respiratory Syncytial Virus Prefusion F Vaccination: Antibody Persistence and Revaccination.
    Walsh EE; Falsey AR; Zareba AM; Jiang Q; Gurtman A; Radley D; Gomme E; Cooper D; Jansen KU; Gruber WC; Swanson KA; Schmoele-Thoma B
    J Infect Dis; 2024 Apr; ():. PubMed ID: 38606958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
    Simões EAF; Madhi SA; Muller WJ; Atanasova V; Bosheva M; Cabañas F; Baca Cots M; Domachowske JB; Garcia-Garcia ML; Grantina I; Nguyen KA; Zar HJ; Berglind A; Cummings C; Griffin MP; Takas T; Yuan Y; Wählby Hamrén U; Leach A; Villafana T
    Lancet Child Adolesc Health; 2023 Mar; 7(3):180-189. PubMed ID: 36634694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine.
    Falsey AR; Walsh EE; Scott DA; Gurtman A; Zareba A; Jansen KU; Gruber WC; Dormitzer PR; Swanson KA; Jiang Q; Gomme E; Cooper D; Schmoele-Thoma B
    J Infect Dis; 2022 Jun; 225(12):2056-2066. PubMed ID: 34931667
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nirsevimab Immunization to Prevent Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants and Children up to 24 Months of Age.
    Cieslak CM
    Nurs Womens Health; 2024 Feb; 28(1):75-79. PubMed ID: 38070539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of Nirsevimab Immunoprophylaxis Administered at Birth to Prevent Infant Hospitalisation for Respiratory Syncytial Virus Infection: A Population-Based Cohort Study.
    Ezpeleta G; Navascués A; Viguria N; Herranz-Aguirre M; Juan Belloc SE; Gimeno Ballester J; Muruzábal JC; García-Cenoz M; Trobajo-Sanmartín C; Echeverria A; Martínez-Baz I; Vera-Punzano N; Casado I; López-Mendoza H; Ezpeleta C; Castilla J
    Vaccines (Basel); 2024 Apr; 12(4):. PubMed ID: 38675765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
    Jones JM; Fleming-Dutra KE; Prill MM; Roper LE; Brooks O; Sánchez PJ; Kotton CN; Mahon BE; Meyer S; Long SS; McMorrow ML
    MMWR Morb Mortal Wkly Rep; 2023 Aug; 72(34):920-925. PubMed ID: 37616235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.
    Griffin MP; Yuan Y; Takas T; Domachowske JB; Madhi SA; Manzoni P; Simões EAF; Esser MT; Khan AA; Dubovsky F; Villafana T; DeVincenzo JP;
    N Engl J Med; 2020 Jul; 383(5):415-425. PubMed ID: 32726528
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nirsevimab: A Review.
    Balbi H
    Pediatr Allergy Immunol Pulmonol; 2024 Mar; 37(1):3-6. PubMed ID: 38484270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater
    Zhao M; Zheng ZZ; Chen M; Modjarrad K; Zhang W; Zhan LT; Cao JL; Sun YP; McLellan JS; Graham BS; Xia NS
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28539438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.
    Blanco JCG; Fernando LR; Zhang W; Kamali A; Boukhvalova MS; McGinnes-Cullen L; Morrison TG
    J Virol; 2019 Dec; 93(23):. PubMed ID: 31511382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploring parental perspectives: Maternal RSV vaccination versus infant RSV monoclonal antibody.
    Treston B; Geoghegan S
    Hum Vaccin Immunother; 2024 Dec; 20(1):2341505. PubMed ID: 38723786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults.
    Baber J; Arya M; Moodley Y; Jaques A; Jiang Q; Swanson KA; Cooper D; Maddur MS; Loschko J; Gurtman A; Jansen KU; Gruber WC; Dormitzer PR; Schmoele-Thoma B
    J Infect Dis; 2022 Dec; 226(12):2054-2063. PubMed ID: 35543281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults.
    Walsh EE; Pérez Marc G; Zareba AM; Falsey AR; Jiang Q; Patton M; Polack FP; Llapur C; Doreski PA; Ilangovan K; Rämet M; Fukushima Y; Hussen N; Bont LJ; Cardona J; DeHaan E; Castillo Villa G; Ingilizova M; Eiras D; Mikati T; Shah RN; Schneider K; Cooper D; Koury K; Lino MM; Anderson AS; Jansen KU; Swanson KA; Gurtman A; Gruber WC; Schmoele-Thoma B;
    N Engl J Med; 2023 Apr; 388(16):1465-1477. PubMed ID: 37018468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis.
    Sun M; Lai H; Na F; Li S; Qiu X; Tian J; Zhang Z; Ge L
    JAMA Netw Open; 2023 Feb; 6(2):e230023. PubMed ID: 36800182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
    Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.